Conflict of interest: Nothing to report
Diagnosis of type II enteropathy-associated T-cell lymphoma should be limited to EBER− cases†
Article first published online: 11 SEP 2012
Copyright © 2012 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 87, Issue 11, pages E129–E130, November 2012
How to Cite
Tan, S.-Y., Nakamura, S., Tan, H.-C., Liu, Y.-h. and Chuang, S.-S. (2012), Diagnosis of type II enteropathy-associated T-cell lymphoma should be limited to EBER− cases. Am. J. Hematol., 87: E129–E130. doi: 10.1002/ajh.23324
- Issue published online: 23 OCT 2012
- Article first published online: 11 SEP 2012
- Accepted manuscript online: 22 AUG 2012 01:06AM EST
- Manuscript Accepted: 10 AUG 2012
- Manuscript Received: 20 JUL 2012
We read with interest the series of Type II enteropathy-associated T-cell lymphoma (EATL) by Tse et al. . As this is a rare disease that is more commonly encountered in Asia, such an attempt to assemble cases from the region in order to define its clinicopathological features is laudable. Nevertheless, we would express some concern over the inclusion of three cases with extensive EBV encoded RNA (EBER) expression in the study. These cases were included because they were morphological mimics of Type II EATL, lacked angiocentricity, and showed clonal rearrangement of TCR gene. Similar cases have been documented to be of T-cell lineage by double labeling and T-cell clonality study . In addition, the lack of features such as angiocentricity and necrosis does not exclude extranodal NK/T-cell lymphoma (ENKL) and this neoplasm may also include cases of both NK and T-cell origins [3, 4]. EBER-positivity is characteristic of ENKL, both in cases with NK-lineage (the majority of cases) or T-cell lineage (around 10% of cases, but up to 27% has been reported) . In contrast, the overwhelming majority of Type II EATL has been shown to be EBER− [6–8] and isolated EBER+ cells in this neoplasm are in fact EBV-infected B-cells (Fig. 1). Type II EATL is a newly recognized entity that needs to be properly defined and understanding of this disease is being accumulated gradually with increasing experience. It would be prudent to keep this entity pure at this stage and limit it to EBER− cases. The occasional EBER+ cases can be incorporated at a later stage when more evidence emerges to support its inclusion.
- 1Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol 2012; 87: 663–668., , , et al.
- 2NK-cell lineage predicts poor survival in primary intestinal NK- and T-cell lymphomas. Am J Surg Pathol 2009; 33: 1230–1240., , , et al.
- 3Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH CE,Harris NL,Jaffe ES, et al., editors. WHO Classification of Tumours of Haemtopoietic and Lymphoid Tissues. Lyon: IARC; 2008. pp 285–288., , , et al.
- 4Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: A comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol 2012; 36: 481–499., , , et al.
- 5Nasal-type extranodal natural killer/T-cell lymphomas: A clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol 2004; 17: 1097–1107., , , et al.
- 6Type II enteropathy-associated T-cell lymphoma: A distinct aggressive lymphoma with frequent gammadelta T-cell receptor expression. Am J Surg Pathol 2011; 35: 1557–1569., , , et al.
- 7The phenotype of intraepithelial lymphocytes in Taiwanese enteropathy-associated T-cell lymphoma is distinct from that of the West. Histopathology 2008; 53: 234–236., , , et al.
- 8CD8+, CD56+ (natural killer-like) T-cell lymphoma involving the small intestine with no evidence of enteropathy: Clinicopathology and molecular study of five Japanese patients. Pathol Int 2008; 58: 626–634., , , et al.
Soo-Yong Tan*, Shigeo Nakamura, Hwan-Cheong Tan*, Yan-hui Liu, Shih-Sung Chuang§, * Department of Pathology, Singapore General Hospital, Singapore, Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan, Department of Pathology, Guangdong General Hospital, Guangzhou, China, § Department of Pathology, Chi-Mei Medical Center, Tainan and Taipei Medical University, Taipei, Taiwan.